Heinz Wiendl
Westfälische Wilhelms-Universität Münster
H-index: 99
Europe-Germany
Top articles of Heinz Wiendl
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making? | Olaf Hoffmann Ralf Gold Sven G Meuth Ralf A Linker Thomas Skripuletz | 2024/2 | |
Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis (P9-6.007) | Heinz Wiendl Jerome de Seze Amit Bar-Or Jorge Correale Anne Cross | 2023/10/1 | |
A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis | Laura Airas Robert A Bermel Tanuja Chitnis Hans-Peter Hartung Jin Nakahara | 2024/4 | |
Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015) | Bernd Kieseier Xavier Montalban Mitzi Williams Laura Airas Sarbjit Saini | 2024/4/14 | |
Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years (P9-6.010) | Heinz Wiendl Stephen Hauser Jacqueline Nicholas Jerome De Seze Sven Meuth | 2024/4/14 | |
Serum neurofilament light and white matter characteristics in the general population: a longitudinal analysis | Geroscience | Marco Hermesdorf Niklas Wulms Aleksandra Maceski David Leppert Pascal Benkert | 2024/2 |
Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study | Muscle & Nerve | James F Howard Jr Tuan Vu Renato Mantegazza Hani Kushlaf Shigeaki Suzuki | 2024/2/21 |
Résultats de l’étude d’extension NOVA évaluant la préférence des patients pour l’administration sous-cutanée (SC) versus intraveineuse (IV) de natalizumab (NTZ) avec le schéma … | Revue Neurologique | Heinz Wiendl John Foley Gilles Defer Lana Zhovtis Ryerson Jeffrey A Cohen | 2024/4/1 |
The Bruton’s Tyrosine Kinase Inhibitor Remibrutinib Exhibits No Impact on Serum Immunoglobulin Levels: Insights from Chronic Spontaneous Urticaria (P10-6.018) | Robert Bermel Warner Carr Tanuja Chitnis Thomas Dörner Koremasa Hayama | 2024/4/14 | |
CSF Specific T Cell Activation Characterizes Neurological Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy (S38. 006) | Louisa Müller-Miny Svea Haessner Frederike Straeten Andreas Schulte-Mecklenbeck Heinz Wiendl | 2024/4/14 | |
Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations | Julia Krämer Heinz Wiendl | 2024/6/1 | |
Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury | Clinical Chemistry and Laboratory Medicine (CCLM) | David Wilson Dandan Chan Lei Chang Robert Mathis Inge Verberk | 2024/1/26 |
Targeted and optimized multi-channel transcranial direct current stimulation for focal epilepsy: An N-of-1 trial | Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation | Marios Antonakakis Fabian Kaiser Stefan Rampp Stjepana Kovac Heinz Wiendl | 2024/2/21 |
Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories | Science Translational Medicine | Catharina C Gross Andreas Schulte-Mecklenbeck Olga V Steinberg Timo Wirth Sarah Lauks | 2024/3/27 |
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients with Relapsing Multiple Sclerosis: Results from Subgroup Analysis Based on Body Mass Index … | Frontiers in immunology | Tjalf Ziemssen Douglas L Arnold Enrique Alvarez Anne H Cross Roman Willi | 2022/3/31 |
Outcomes of COVID-19 in Ofatumumab-treated Patients with RMS: Data from the ALITHIOS Open-label Extension Study (P1-6.010) | Ibolya Boer Bruce Cree Heinz Wiendl Anne Cross Sylvia Delgado | 2024/4/14 | |
Quantitative Analysis of Retinal Perfusion in Patients with Frontotemporal Dementia Using Optical Coherence Tomography Angiography | Diagnostics | Eliane Luisa Esser Larissa Lahme Sebastian Dierse Raphael Diener Nicole Eter | 2024/1/18 |
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis | Journal of Neurology, Neurosurgery & Psychiatry | Nicolás Fissolo Pascal Benkert Jaume Sastre-Garriga Neus Mongay-Ochoa Andreu Vilaseca-Jolonch | 2024/5/1 |
Complement activation is associated with disease severity in multiple sclerosis | Neurology: Neuroimmunology & Neuroinflammation | Johanna Oechtering Kerstin Stein Sabine A Schaedelin Aleksandra M Maceski Annette Orleth | 2024/2/14 |
Functional Signature of LRP4 Antibodies in Myasthenia Gravis | Neurology: Neuroimmunology & Neuroinflammation | Omar Chuquisana Frauke Stascheit Christian W Keller Maja Pučić-Baković Anne-Marie Patenaude | 2024/3/20 |
Co-Authors
